Literature DB >> 19669530

Hydroxymethylnitrofurazone:dimethyl-beta-cyclodextrin inclusion complex: a physical-chemistry characterization.

Renato Grillo1, Nathalie Ferreira Silva Melo, Carolina Morales Moraes, André Henrique Rosa, José Arnaldo Frutuoso Roveda, Carla M S Menezes, Elizabeth Igne Ferreira, Leonardo Fernandes Fraceto.   

Abstract

Hydroxymethylnitrofurazone (NFOH) is active against Trypanosoma cruzi; however, its low solubility and high toxicity precludes its current use in treatment of parasitosis. Cyclodextrin can be used as a drug carrier system, as it is able to form inclusion (host-guest) complexes with a wide variety of organic (guest) molecules. Several reports have shown the interesting use of modified beta-cyclodextrins in pharmaceutical formulation, to improve the bioavailability of drugs and to decrease their toxicity. The aim of this work was to characterize inclusion complexes formed between NFOH and dimethyl-beta-cyclodextrin (DM-beta-CD) by complexation/release kinetics and solubility isotherm experiments using ultraviolet (UV)-visible spectrophotometry and by the measurement of the dynamics information obtained from T(1) relaxation times and diffusion (DOSY) experiments using nuclear magnetic resonance (NMR) spectroscopy. The complex was prepared at different NFOH and DM-beta-CD molar ratios. The UV-visible measurements were recorded in a spectrophotometer, and NMR experiments were recorded at 20 degrees C on a NMR spectrometer (Varian Inova) operating at 500 MHz. Longitudinal relaxation times were obtained by the conventional inversion-recovery method and the DOSY experiments were carried out using the BPPSTE sequence. The kinetics of complexation revealed that 30 h is enough for stabilization of the NFOH absorbance in presence of cyclodextrin. Solubility isotherm studies show a favorable complexation and increase in solubility when NFOH interacts with cyclodextrin. The analysis of the NMR-derived diffusion coefficients and T(1) relaxation times shows that in the presence of DM-beta-CD, NFOH decreases its mobility in solution, indicating that this antichagasic compound interacts with the cyclodextrin cavity. The release kinetics assays showed that NFOH changes its release profile when in the presence of cyclodextrin due to complexation. This study was focused on the physicochemical characterization of drug-delivery formulations that may serve as potentially new therapeutic options for the treatment of Chagas' disease.

Entities:  

Year:  2008        PMID: 19669530      PMCID: PMC2565764          DOI: 10.1007/s10867-008-9054-7

Source DB:  PubMed          Journal:  J Biol Phys        ISSN: 0092-0606            Impact factor:   1.365


  15 in total

1.  The Stability of Cyclodextrin Complexes in Solution.

Authors:  Kenneth A. Connors
Journal:  Chem Rev       Date:  1997-08-05       Impact factor: 60.622

2.  NMR diffusion as a novel tool for measuring the association constant between cyclodextrin and guest molecules.

Authors:  Reinhard Wimmer; Finn L Aachmann; Kim L Larsen; Steffen B Petersen
Journal:  Carbohydr Res       Date:  2002-04-30       Impact factor: 2.104

3.  Use of 1H-NMR spectroscopy to determine the enantioselective mechanism of neutral and anionic cyclodextrins in capillary electrophoresis.

Authors:  P K Owens; A F Fell; M W Coleman; M Kinns; J C Berridge
Journal:  J Pharm Biomed Anal       Date:  1997-06       Impact factor: 3.935

Review 4.  Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery.

Authors:  R A Rajewski; V J Stella
Journal:  J Pharm Sci       Date:  1996-11       Impact factor: 3.534

5.  Evaluation of cyclodextrin solubilization of drugs.

Authors:  Thorsteinn Loftsson; Dagný Hreinsdóttir; Már Másson
Journal:  Int J Pharm       Date:  2005-09-30       Impact factor: 5.875

Review 6.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.

Authors:  T Loftsson; M E Brewster
Journal:  J Pharm Sci       Date:  1996-10       Impact factor: 3.534

7.  Novel non-acidic formulations of haloperidol complexed with beta-cyclodextrin derivatives.

Authors:  Y L Loukas; V Vraka; G Gregoriadis
Journal:  J Pharm Biomed Anal       Date:  1997-10       Impact factor: 3.935

8.  Study of the interaction between S(--) bupivacaine and 2-hydroxypropyl-beta-cyclodextrin.

Authors:  Carolina Morales Moraes; Priscila Abrami; Eneida de Paula; Angélica F A Braga; Leonardo Fernandes Fraceto
Journal:  Int J Pharm       Date:  2006-10-05       Impact factor: 5.875

9.  Development and pharmacological evaluation of ropivacaine-2-hydroxypropyl-beta-cyclodextrin inclusion complex.

Authors:  Daniele R de Araujo; Simone S Tsuneda; Cíntia M S Cereda; Fernanda Del G F Carvalho; Paulo S C Preté; Sergio A Fernandes; Fabiano Yokaichiya; Margareth K K D Franco; Irineu Mazzaro; Leonardo F Fraceto; Angélica de F A Braga; Eneida de Paula
Journal:  Eur J Pharm Sci       Date:  2007-10-07       Impact factor: 4.384

10.  Drug-delivery systems for local anesthetics: therapeutic applications.

Authors:  Daniele Ribeiro de Araújo; Luciana de Matos Alves Pinto; Angélica de Fátima de Assunção Braga; Eneida de Paula
Journal:  Rev Bras Anestesiol       Date:  2003-09       Impact factor: 0.964

View more
  3 in total

1.  Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease.

Authors:  Teresa Vinuesa; Rocio Herráez; Laura Oliver; Elisa Elizondo; Argia Acarregui; Amaia Esquisabel; Jose Luis Pedraz; Nora Ventosa; Jaume Veciana; Miguel Viñas
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

2.  Characterization and trypanocidal activity of a β-lapachone-containing drug carrier.

Authors:  Juliana M C Barbosa; Caroline D Nicoletti; Patrícia B da Silva; Tatiana G Melo; Débora O Futuro; Vitor F Ferreira; Kelly Salomão
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.752

Review 3.  Drug/Lead Compound Hydroxymethylation as a Simple Approach to Enhance Pharmacodynamic and Pharmacokinetic Properties.

Authors:  Soraya S Santos; Rodrigo V Gonzaga; Cauê B Scarim; Jeanine Giarolla; Marina C Primi; Chung M Chin; Elizabeth I Ferreira
Journal:  Front Chem       Date:  2022-02-14       Impact factor: 5.221

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.